Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.82 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.75 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8261934 | 0.91 | DNMT3A (0.84) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL1144104 | 0.91 | DNMT3A (0.75) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL29808416 | 0.90 | DNMT3A (1.00) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL1144242 | 0.90 | DNMT3A (1.00) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL11358623 | 0.90 | DNMT3A (0.82) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL18029599 | 0.90 | DNMT3A (0.82) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL1144106 | 0.90 | DNMT3A (0.73) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL21586535 | 0.89 | DNMT3A (0.80) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL7026343 | 0.89 | DNMT3A (0.80) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL7029521 | 0.89 | DNMT3A (0.80) | DNMT3AHDAC1HDAC6NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637519-B1 | Crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1637519-A1 | Crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| EP-1173418-B1 | CRYSTALLINE FORM 3 OF THE SODIUM SALT OF 5- CHLORO -2- METHOXY -N- (2- (4-METHOXY -3- METHYL AMINOTHIO CARBONYLAMINO SULFONYLPHENYL) ETHYL) BENZAMIDE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6723751-B1 | INDIVIDUAL POLYMORPHIC FORMS OF CRYSTALLINE SODIUM SALT HAVING SPECIFIED X-RAY DIFFRACTION SPECTRA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-04-20 | — | — | US | disclosed |
| EP-1173418-A1 | CRYSTALLINE FORMS OF THE SODIUM SALT OF 5- CHLORO -2- METHOXY -N- (2- (4-METHOXY -3- METHYL AMINOTHIO CARBONYLAMINO SULFONYLPHENYL) ETHYL) BENZAMIDE | Aventis Pharma Deutschland GmbH (DE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000063167-A1 | CRYSTALLINE FORMS OF THE SODIUM SALT OF 5- CHLORO -2- METHOXY -N- (2- (4-METHOXY -3- METHYL AMINOTHIO CARBONYLAMINO SULFONYLPHENYL) ETHYL) BENZAMIDE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-10-26 | — | — | WO | disclosed |